Your session is about to expire
← Back to Search
Brexpiprazole (OPC-34712) for Schizophrenia
Study Summary
This trial will test if the drug brexpiprazole is safe and effective in treating adolescents with schizophrenia.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 316 Patients • NCT03198078Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the age limit for this trial set at 40 years or older?
"As this study's inclusion criteria demonstrates, the youngest patients that can take part in this trial are 13 years old while the oldest participants can be 17."
Could you give me the screening criteria for this clinical trial?
"The target recruitment for this clinical trial investigating a new medication for adolescents with schizophrenia is 315 patients. The ages of the patients must be between 13-17 and they must have a current PANSS score that is >= 80."
Can patients still enroll in this research project?
"This clinical trial, which was first posted on 2017-06-30, is looking for participants as of the most recent update on 2022-08-31."
What similar research has been conducted on Brexpiprazole (OPC-34712)?
"As of now, there are 10 Phase 3 trials and 19 total live studies for Brexpiprazole (OPC-34712). The majority of these studies are based in Hamilton, Ontario, but there are 37 clinical trial locations for Brexpiprazole (OPC-34712) in total."
Has the Food and Drug Administration given its okay to Brexpiprazole (OPC-34712)?
"OPC-34712, or Brexpiprazole, is considered to be safe based on its classification as a Phase 3 trial drug."
For what purpose is Brexpiprazole most commonly prescribed?
"While typically used to treat acute coryza, Brexpiprazole (OPC-34712) can also be used as an antidepressive agent, or to help with irritability and agitation."
Share this study with friends
Copy Link
Messenger